Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Molecules ; 27(2)2022 Jan 15.
Article in English | MEDLINE | ID: mdl-35056859

ABSTRACT

A series of histamine (HST)-related compounds were synthesized and tested for their activating properties on five physiologically relevant human Carbonic Anhydrase (hCA) isoforms (I, II, Va, VII and XIII). The imidazole ring of HST was replaced with different 5-membered heterocycles and the length of the aliphatic chain was varied. For the most interesting compounds some modifications on the terminal amino group were also performed. The most sensitive isoform to activation was hCA I (KA values in the low micromolar range), but surprisingly none of the new compounds displayed activity on hCA II. Some derivatives (1, 3a and 22) displayed an interesting selectivity for activating hCA I over hCA II, Va, VII and XIII.


Subject(s)
Carbonic Anhydrase I/metabolism , Heterocyclic Compounds, 4 or More Rings/chemistry , Heterocyclic Compounds, 4 or More Rings/pharmacology , Histamine/chemistry , Histamine/pharmacology , Carbonic Anhydrase I/drug effects , Carbonic Anhydrase II/drug effects , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase V/drug effects , Carbonic Anhydrase V/metabolism , Carbonic Anhydrases/drug effects , Carbonic Anhydrases/metabolism , Heterocyclic Compounds, 4 or More Rings/chemical synthesis , Histamine/analogs & derivatives , Histamine/chemical synthesis , Humans , Imidazoles/chemistry , Protein Isoforms/drug effects , Protein Isoforms/metabolism
2.
Int J Mol Sci ; 21(5)2020 Mar 04.
Article in English | MEDLINE | ID: mdl-32143488

ABSTRACT

l-Carnosine (ß-Ala-l-His) and several other histidine-containing peptides, including two N-methylated forms on the imidazole ring (l-anserine and l-balenine), two derivatives modified on the carboxyl function (carcinine and l-carnosinamide), two analogues differing in the length of the N-terminal residue (l-homocarnosine and Gly-l-His) and the N-acetyl derivatives, were investigated as activators of four isoforms of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The four human isoforms hCA I, II, VA and IX were activated in the low to high micromolar range, with a rather complex structure activity relationship. A performed computational study allowed us to rationalize these results and to propose a binding mode of these activators within the enzyme active site. Similarly to other CA activators, the here studied peptides could find relevant pharmacological applications such as in the management of CA deficiencies, for therapy memory and enhancing cognition or for artificial tissues engineering.


Subject(s)
Carbonic Anhydrases/metabolism , Carnosine/chemistry , Dipeptides/chemistry , Histidine/chemistry , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase IX/metabolism , Carbonic Anhydrase V/metabolism , Carnosine/analogs & derivatives , Chelating Agents/pharmacology , Humans , Kinetics , Models, Molecular , Protein Domains , Protons , Software
3.
Biochim Biophys Acta Mol Basis Dis ; 1863(4): 929-935, 2017 04.
Article in English | MEDLINE | ID: mdl-28131914

ABSTRACT

Events responsible for cerebrovascular disease in diabetes are not fully understood. Pericyte loss is an early event that leads to endothelial cell death, microaneurysms, and cognitive impairment. A biochemical mechanism underlying pericyte loss is rapid respiration (oxidative metabolism of glucose). This escalation in respiration results from free influx of glucose into insulin-insensitive tissues in the face of high glucose levels in the blood. Rapid respiration generates superoxide, the precursor to all reactive oxygen species (ROS), and results in pericyte death. Respiration is regulated by carbonic anhydrases (CAs) VA and VB, the two isozymes expressed in mitochondria, and their pharmacologic inhibition with topiramate reduces respiration, ROS, and pericyte death. Topiramate inhibits both isozymes; therefore, in the earlier studies, their individual roles were not discerned. In a recent genetic study, we showed that mitochondrial CA VA plays a significant role in regulation of reactive oxygen species and pericyte death. The role of CA VB was not addressed. In this report, genetic knockdown and overexpression studies confirm that mitochondrial CA VA regulates respiration in pericytes, whereas mitochondrial CA VB does not contribute significantly. Identification of mitochondrial CA VA as a sole regulator of respiration provides a specific target to develop new drugs with fewer side effects that may be better tolerated and can protect the brain from diabetic injury. Since similar events occur in the capillary beds of other insulin-insensitive tissues such as the eye and kidney, these drugs may also slow the onset and progression of diabetic disease in these tissues.


Subject(s)
Apoptosis , Brain/enzymology , Carbonic Anhydrase V/metabolism , Cerebrovascular Disorders/enzymology , Diabetic Angiopathies/prevention & control , Mitochondria/enzymology , Mitochondrial Proteins/metabolism , Pericytes/enzymology , Animals , Brain/pathology , Carbonic Anhydrase V/genetics , Cell Line, Transformed , Cerebrovascular Disorders/genetics , Cerebrovascular Disorders/pathology , Diabetic Angiopathies/enzymology , Diabetic Angiopathies/genetics , Diabetic Angiopathies/pathology , Mice , Mitochondria/pathology , Mitochondrial Proteins/genetics , Pericytes/pathology
4.
J Biomol Struct Dyn ; 35(2): 449-461, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26828699

ABSTRACT

Mitochondrial carbonic anhydrase VA (CAVA) catalyzes the hydration of carbon dioxide to produce proton and bicarbonate which is primarily expressed in the mitochondrial matrix of liver, and involved in numerous physiological processes including lipogenesis, insulin secretion from pancreatic cells, ureagenesis, gluconeogenesis, and neuronal transmission. To understand the effect of pH on the structure, function, and stability of CAVA, we employed spectroscopic techniques such as circular dichroism, fluorescence, and absorbance measurements in wide range of pH (from pH 2.0 to pH 11.5). CAVA showed an aggregation at acidic pH range from pH 2.0 to pH 5.0. However, it remains stable and maintains its secondary structure in the pH range, pH 7.0-pH 11.5. Furthermore, this enzyme has an appreciable activity at more than pH 7.0 (7.0 < pH ≤ 11.5) with maximum activity at pH 9.0. The maximal values of kcat and kcat/Km at pH 9.0 are 3.7 × 106 s-1 and 5.5 × 107 M-1 s-1, respectively. However, this enzyme loses its activity in the acidic pH range. We further performed 20-ns molecular dynamics simulation of CAVA to see the dynamics at different pH values. An excellent agreement was observed between in silico and in vitro studies. This study provides an insight into the activity of CAVA in the pH range of subcellular environment.


Subject(s)
Carbonic Anhydrase V/chemistry , Hydrogen-Ion Concentration , Models, Molecular , Protein Conformation , Carbonic Anhydrase V/metabolism , Enzyme Activation , Enzyme Stability , Spectrum Analysis , Structure-Activity Relationship
5.
Proc Natl Acad Sci U S A ; 110(18): 7423-8, 2013 Apr 30.
Article in English | MEDLINE | ID: mdl-23589845

ABSTRACT

Prior studies with carbonic anhydrase (CA) inhibitors implicated mitochondrial CA in ureagenesis and gluconeogenesis. Subsequent studies identified two mitochondrial CAs. To distinguish the contribution of each enzyme, we studied the effects of targeted disruption of the murine CA genes, called Car5A and Car5B. The Car5A mutation had several deleterious consequences. Car5A null mice were smaller than wild-type littermates and bred poorly. However, on sodium-potassium citrate-supplemented water, they produced offspring in expected numbers. Their blood ammonia concentrations were markedly elevated, but their fasting blood sugars were normal. By contrast, Car5B null mice showed normal growth and normal blood ammonia levels. They too had normal fasting blood sugars. Car5A/B double-knockout (DKO) mice showed additional abnormalities. Impaired growth was more severe than for Car5A null mice. Hyperammonemia was even greater as well. Although fertile, DKO animals were produced in less-than-predicted numbers even when supplemented with sodium-potassium citrate in their drinking water. Survival after weaning was also reduced, especially for males. In addition, fasting blood glucose levels for DKO mice were significantly lower than for controls (153 ± 33 vs. 230 ± 24 mg/dL). The enhanced hyperammonemia and lower fasting blood sugar, which are both seen in the DKO mice, indicate that both Car5A and Car5B contribute to both ammonia detoxification (ureagenesis) and regulation of fasting blood sugar (gluconeogenesis). Car5A, which is expressed mainly in liver, clearly has the predominant role in ammonia detoxification. The contribution of Car5B to ureagenesis and gluconeogenesis was evident only on a Car5A null background.


Subject(s)
Ammonia/metabolism , Carbonic Anhydrase V/genetics , Gene Targeting , Glucose/metabolism , Mitochondria/enzymology , Mutagenesis/genetics , Ammonia/blood , Animals , Blood Glucose/metabolism , Carbonic Anhydrase V/metabolism , Female , Genotype , Inactivation, Metabolic , Male , Mice , Mice, Knockout , RNA, Messenger/genetics , RNA, Messenger/metabolism , Survival Analysis , Weight Gain
6.
Bioorg Med Chem ; 21(6): 1544-8, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-22854196

ABSTRACT

Obesity is quickly becoming an increasing problem in the developed world. One of the major fundamental causes of obesity and diabetes is mitochondria dysfunction due to faulty metabolic pathways which alter the metabolic substrate flux resulting in the development of these diseases. This paper examines the role of mitochondrial carbonic anhydrase (CA) isozymes in the metabolism of pyruvate, acetate, and succinate when specific isozyme inhibitors are present. Using a sensitive electrochemical approach of wired mitochondria to analytically measure metabolic energy conversion, we determine the resulting metabolic difference after addition of an inhibitory compound. We found that certain sulfonamide analogues displayed broad spectrum inhibition of metabolism, where others only had significant effect on some metabolic pathways. Pyruvate metabolism always displayed the most dramatically affected metabolism by the sulfonamides followed by fatty acid metabolism, and then finally succinate metabolism. This allows for the possibility of using designed sulfonamide analogues to target specific mitochondrial CA isozymes in order to subtly shift metabolism and glucogenesis flux to treat obesity and diabetes.


Subject(s)
Carbonic Anhydrase Inhibitors/metabolism , Carbonic Anhydrase V/metabolism , Mitochondria/metabolism , Sulfonamides/metabolism , Animals , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase V/antagonists & inhibitors , Electrochemical Techniques , Electrodes , Energy Metabolism , Fatty Acids/metabolism , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Mice , Mice, Inbred C57BL , Pyruvic Acid/metabolism , Succinic Acid/metabolism , Sulfonamides/chemistry
7.
PLoS One ; 7(6): e39881, 2012.
Article in English | MEDLINE | ID: mdl-22745834

ABSTRACT

The regulation of the acid-base balance in cells is essential for proper cellular homeostasis. Disturbed acid-base balance directly affects cellular physiology, which often results in various pathological conditions. In every living organism, the protein family of carbonic anhydrases regulate a broad variety of homeostatic processes. Here we describe the identification, mapping and cloning of a zebrafish carbonic anhydrase 5 (ca5) mutation, collapse of fins (cof), which causes initially a collapse of the medial fins followed by necrosis and rapid degeneration of the embryo. These phenotypical characteristics can be mimicked in wild-type embryos by acetazolamide treatment, suggesting that CA5 activity in zebrafish is essential for a proper development. In addition we show that CA5 regulates acid-base balance during embryonic development, since lowering the pH can compensate for the loss of CA5 activity. Identification of selective modulators of CA5 activity could have a major impact on the development of new therapeutics involved in the treatment of a variety of disorders.


Subject(s)
Carbonic Anhydrase V/metabolism , Zebrafish Proteins/metabolism , Acid-Base Equilibrium/genetics , Acid-Base Equilibrium/physiology , Animals , Carbonic Anhydrase V/genetics , Embryonic Development , Homeostasis/genetics , Homeostasis/physiology , Hydrogen-Ion Concentration , Zebrafish , Zebrafish Proteins/genetics
8.
Cancer Biomark ; 11(1): 1-14, 2011.
Article in English | MEDLINE | ID: mdl-22820136

ABSTRACT

BACKGROUND: We sought to validate global microarray results indicating the differential expression of 383 genes in Peripheral Blood Mononuclear Cells (PBMCs) from patients with pancreatic cancer (PC) and to further evaluate their PC diagnostic potential. METHODS AND MATERIALS: In total, 177 patients were recruited (47 healthy controls (HC), 35 chronic pancreatitis (CP) patients, and 95 PC patients). PBMC expressions of six genes from our previous study (ANXA3, ARG1, CA5B, F5, SSBP2, and TBC1D8) along with four new genes (MIC1, NGAL, MUC1, and MUC16) were analyzed using multiplex Q-RT PCR. RESULTS: Differential expressions of 5 of the 6 genes previously identified by PBMC microarray were validated in this study. Multivariate models for PBMC gene expression were attempted to determine if any combination was diagnostically superior to CA19-9 alone. We found that addition of PBMC CA5B, F5, SSBP2, and MIC1 expression levels to CA19-9 significantly improved CA19-9's diagnostic abilities when comparing resectable PC to CP patients (p=0.023). CONCLUSIONS: Results of our previous study were validated, indicating reproducibility of PC-associated PBMC expression profiling. We identified a score-based model that can differentiate resectable PC from CP better than CA19-9, potentiating that PBMC differential expression analysis may offer a novel tool for early PC diagnosis.


Subject(s)
Early Detection of Cancer , Leukocytes, Mononuclear/metabolism , Pancreatic Neoplasms/blood , Aged , Area Under Curve , CA-19-9 Antigen/genetics , CA-19-9 Antigen/metabolism , Carbonic Anhydrase V/genetics , Carbonic Anhydrase V/metabolism , Case-Control Studies , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Factor V/genetics , Factor V/metabolism , Female , Growth Differentiation Factor 15/genetics , Growth Differentiation Factor 15/metabolism , Humans , Male , Middle Aged , Molecular Diagnostic Techniques , Multiplex Polymerase Chain Reaction , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/genetics , ROC Curve , Real-Time Polymerase Chain Reaction , Transcription, Genetic , Transcriptome
9.
Bioorg Med Chem Lett ; 15(9): 2315-20, 2005 May 02.
Article in English | MEDLINE | ID: mdl-15837316

ABSTRACT

The antiepileptic drug zonisamide was considered to act as a weak inhibitor of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) (with a K(I) of 4.3 microM against the cytosolic isozyme II). Here we prove that this is not true. Indeed, testing zonisamide in the classical assay conditions of the CO2 hydrase activity of hCA II, with incubation times of enzyme and inhibitor solution of 15 min, a K(I) of 10.3 microM has been obtained. However, when the incubation between enzyme and inhibitor was prolonged to 1 h, the obtained K(I) was of 35.2 nM, of the same order of magnitude as that of the clinically used sulfonamides/sulfamates acetazolamide, methazolamide, ethoxzolamide and topiramate (K(I)s in the range of 5.4-15.4 nM). The inhibition of the human mitochondrial isozyme hCA V with these compounds has been also tested by means of a dansylamide competition binding assay, which showed zonisamide and topiramate to be effective inhibitors, with K(I)s in the range of 20.6-25.4 nM. The X-ray crystal structure of the adduct of hCA II with zonisamide has also been solved at a resolution of 1.70 A, showing that the sulfonamide moiety participates in the classical interactions with the Zn(II) ion and the residues Thr199 and Glu106, whereas the benzisoxazole ring is oriented toward the hydrophobic half of the active site, establishing a large number of strong van der Waals interactions (<4.5 A) with residues Gln92, Val121, Phe131, Leu198, Thr200, Pro202.


Subject(s)
Carbonic Anhydrase II/chemistry , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrase V/chemistry , Carbonic Anhydrase V/metabolism , Isoxazoles/pharmacology , Binding Sites , Carbonic Anhydrase Inhibitors/chemistry , Crystallography, X-Ray , Cytosol/enzymology , Humans , Isoxazoles/chemistry , Kinetics , Mitochondria/enzymology , Models, Molecular , Protein Conformation , Zonisamide
10.
Bioorg Med Chem Lett ; 14(23): 5763-7, 2004 Dec 06.
Article in English | MEDLINE | ID: mdl-15501037

ABSTRACT

A detailed inhibition study of five carbonic anhydrase (CA, EC 4.2.1.1) isozymes with inorganic phosphates, carbamoyl phosphate, the antiviral phosphonate foscarnet as well as formate is reported. The cytosolic isozyme hCA I was weakly inhibited by neutral phosphate, strongly inhibited by carbamoyl phosphate (K(I) of 9.4 microM), and activated by hydrogen- and dihydrogenphosphate, foscarnet and formate (best activator foscarnet, K(A)=12 microM). The cytosolic isozyme hCA II was weakly inhibited by all the investigated anions, with carbamoyl phosphate showing a K(I) of 0.31 mM. The membrane-associated isozyme hCA IV was the most sensitive to inhibition by phosphates/phosphonates, showing a K(I) of 84 nM for PO(4)(3-), of 9.8 microM for HPO(4)(2-), and of 9.9 microM for carbamoyl phosphate. Foscarnet was the best inhibitor of this isozyme (K(I) of 0.82 mM) highly abundant in the kidneys, which may explain some of the renal side effects of the drug. The mitochondrial isozyme hCA V was weakly inhibited by all phosphates/phosphonates, except carbamoyl phosphate, which showed a K(I) of 8.5 microM. Thus, CA V cannot be the isozyme involved in the carbamoyl phosphate synthetase I biosynthetic reaction, as hypothesized earlier. Furthermore, the relative resistance of CA V to inhibition by inorganic phosphates suggests an evolutionary adaptation of this mitochondrial isozyme to the presence of high concentrations of such anions in these energy-converting organelles, where high amounts of ATP are produced by ATP synthetase, from ADP and inorganic phosphates. The transmembrane, tumor-associated isozyme hCA IX was on the other hand slightly inhibited by all these anions.


Subject(s)
Antiviral Agents/metabolism , Carbamyl Phosphate/metabolism , Carbonic Anhydrase Inhibitors/metabolism , Foscarnet/metabolism , Phosphates/metabolism , Antiviral Agents/chemistry , Carbamyl Phosphate/chemistry , Carbonic Anhydrase IV/antagonists & inhibitors , Carbonic Anhydrase IV/metabolism , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase V/antagonists & inhibitors , Carbonic Anhydrase V/metabolism , Foscarnet/chemistry , Isoenzymes/chemistry , Isoenzymes/metabolism , Phosphates/chemistry
11.
Bioorg Med Chem Lett ; 13(17): 2857-61, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-14611844

ABSTRACT

In addition to sulfonamides, metal complexing anions represent the second class of inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). The first inhibition study of the mitochondrial isozyme CA V (of murine and human origin) with anions is reported here. Inhibition data of the cytosolic isozymes CA I and CA II as well as the membrane-bound isozyme CA IV with a large number of anionic species such as halides, pseudohalides, bicarbonate, nitrate, hydrosulfide, arsenate, sulfamate, and sulfamidate and so on, are also provided for comparison. Isozyme V has an inhibition profile by anions completely different to those of CA I and IV, but similar to that of hCA II, which may have interesting physiological consequences. Similarly to hCA II, the mitochondrial isozymes show micro-nanomolar affinity for sulfonamides such as sulfanilamide and acetazolamide.


Subject(s)
Anions/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrase V/antagonists & inhibitors , Mitochondria/enzymology , Animals , Carbon Dioxide/metabolism , Carbonic Anhydrase V/metabolism , Catalysis , Humans , Isoenzymes , Kinetics , Mice , Sulfonamides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...